Literature DB >> 29861384

Early increases in serum FGF21 levels predict mortality of septic patients.

Xing Li1, Zexiang Zhu2, Tinghong Zhou1, Xiaoyu Cao1, Ting Lu1, Yan Liang1, Jiafen He1, Chuankai Liu1, Zhoulin Dou1, Bin Shen1.   

Abstract

BACKGROUND: Potential prognostic biomarkers for patients with sepsis have yet to be identified. The present study evaluated the prognostic value of fibroblast growth factor 21 (FGF21) levels in patients with sepsis.
METHODS: A total of 120 consecutive Chinese patients with sepsis were prospectively included, and serum levels of FGF21 and biomarkers such as interleukin (IL)-6, tumor necrosis factor alpha (TNF-α), IL-10, procalcitonin (PCT), C-reactive protein (CRP), and lactate (LAC) were measured within 24 h after intensive care unit admission. The demographic and clinical characteristics including underlying diseases, Sequential Organ Failure Assessment (△SOFA), and acute physiology and chronic health evaluation II (APACHE II) scores were recorded. Patients were categorized into survival and non-survival groups according to the 28-day mortality. Correlations between FGF21, serum indicators, severity score and 28-day mortality were analyzed, and Cox regression analysis was performed to identify prognostic factors. Receiver operating characteristic (ROC) curve analysis was used to determine the optimal cut-off of FGF21 for survival prediction.
RESULTS: Non-survivors had significantly higher levels of FGF21, IL-6, TNF-α, IL-10, PCT, CRP, and LAC as well as higher SOFA and APACHE II scores compared with the survivors. FGF21 levels were positively correlated with age, waist circumference, levels of IL-6, IL-10, TNF- α, PCT, CRP, and LAC, △SOFA and APACHE II scores. ROC curves showed that FGF21 had a high sensitivity of 81.3% and specificity of 89.8% for predicting 28-day mortality. Patients with a FGF21 levels <3200 pg/ml had a significantly better survival rate than those with levels >3200 pg/ml, and thus, FGF21 was an independent prognostic factor for survival.
CONCLUSION: FGF21 could serve as a new prognostic biomarker for sepsis survival.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarkers; Fibroblast growth factor 21; Prognosis; Sepsis

Mesh:

Substances:

Year:  2018        PMID: 29861384     DOI: 10.1016/j.cyto.2018.05.020

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  6 in total

1.  Hepatic FGF21 preserves thermoregulation and cardiovascular function during bacterial inflammation.

Authors:  Sarah C Huen; Andrew Wang; Kyle Feola; Reina Desrouleaux; Harding H Luan; Richard Hogg; Cuiling Zhang; Qing-Jun Zhang; Zhi-Ping Liu; Ruslan Medzhitov
Journal:  J Exp Med       Date:  2021-08-18       Impact factor: 14.307

Review 2.  Research Progress of Fibroblast Growth Factor 21 in Fibrotic Diseases.

Authors:  Min-Qi Jia; Cha-Xiang Guan; Jia-Hao Tao; Yong Zhou
Journal:  Oxid Med Cell Longev       Date:  2022-05-29       Impact factor: 7.310

3.  Serum fibroblast growth factor 21 levels after out of hospital cardiac arrest are associated with neurological outcome.

Authors:  Pirkka T Pekkarinen; Markus B Skrifvars; Ville Lievonen; Pekka Jakkula; Laura Albrecht; Pekka Loisa; Marjaana Tiainen; Ville Pettilä; Matti Reinikainen; Johanna Hästbacka
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

4.  Association Between Red Cell Distribution Width and Hospital Mortality in Patients with Sepsis.

Authors:  Yide Li; Yingfang She; Le Fu; Ruitong Zhou; Wendi Xiang; Liang Luo
Journal:  J Int Med Res       Date:  2021-04       Impact factor: 1.671

5.  Close association between lifestyle and circulating FGF21 levels: A systematic review and meta-analysis.

Authors:  Zonghao Qian; Yucong Zhang; Ni Yang; Hao Nie; Zhen Yang; Pengcheng Luo; Xiuxian Wei; Yuqi Guan; Yi Huang; Jinhua Yan; Lei Ruan; Cuntai Zhang; Le Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-25       Impact factor: 6.055

6.  Does an increase in serum FGF21 level predict 28-day mortality of critical patients with sepsis and ARDS?

Authors:  Xing Li; Hua Shen; Tinghong Zhou; Xiaoyu Cao; Ying Chen; Yan Liang; Ting Lu; Jiafen He; Zhoulin Dou; Chuankai Liu; Yong Tang; Zexiang Zhu
Journal:  Respir Res       Date:  2021-06-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.